Details for New Drug Application (NDA): 207981
✉ Email this page to a colleague
The generic ingredient in LONSURF is tipiracil hydrochloride; trifluridine. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.
Summary for 207981
Tradename: | LONSURF |
Applicant: | Taiho Oncology |
Ingredient: | tipiracil hydrochloride; trifluridine |
Patents: | 6 |
Pharmacology for NDA: 207981
Mechanism of Action | Nucleic Acid Synthesis Inhibitors Thymidine Phosphorylase Inhibitors |
Suppliers and Packaging for NDA: 207981
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981 | NDA | Taiho Pharmaceutical Co., Ltd. | 64842-1020 | 64842-1020-1 | 20 TABLET, FILM COATED in 1 BOTTLE (64842-1020-1) |
LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981 | NDA | Taiho Pharmaceutical Co., Ltd. | 64842-1020 | 64842-1020-2 | 40 TABLET, FILM COATED in 1 BOTTLE (64842-1020-2) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 6.14MG BASE;15MG | ||||
Approval Date: | Sep 22, 2015 | TE: | AB | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Feb 22, 2026 | ||||||||
Regulatory Exclusivity Use: | TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 3, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN SEVERELY RENALLY IMPAIRED PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN THERAPY, AN ANTI-VEGF BIOLOGIC, AND IF RAS WILD-TYPE, ANTI-EGFR THERAPY | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 3, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF METASTATIC GASTRIC OR GJA IN SEVERELY RENALLY IMPAIRED PATIENTS TREATED WITH AT LEAST TWO LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY |
Expired US Patents for NDA 207981
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-001 | Sep 22, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-002 | Sep 22, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-002 | Sep 22, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-001 | Sep 22, 2015 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription